According to CDC recommendations, the recombinant zoster vaccine should be administered to which group of people?

The recombinant zoster vaccine is specifically recommended for immunocompetent adults aged 50 and older. This age group is targeted because the risk of developing shingles and its complications increases significantly as people age. The vaccine boosts the immune response to the varicella-zoster virus, which causes shingles, and is an important preventive measure for older adults who may be at greater risk for severe disease. Administering the vaccine to this population helps reduce the incidence of shingles and the potential for postherpetic neuralgia, a painful condition that can follow shingles.

While the vaccine may be beneficial for individuals with a history of shingles, the primary recommendation focuses on the immunocompetent population aged 50 and older, emphasizing the importance of age as a key factor in determining the target demographic for vaccination.